Organogenesis Holdings INC Form 4 insider transactions

Patrick Bilbo, Chief Operating Officer of Organogenesis Holdings Inc., reports the disposal of Class A Common Stock to cover tax obligations.

Lori Freedman, Chief Admin. and Legal Officer of Organogenesis Holdings Inc., reports changes in beneficial ownership of Class A Common Stock due to tax withholding.

David Francisco, CFO of Organogenesis Holdings Inc., reports the disposal of Class A Common Stock to cover tax obligations.

Alan A. Ades, a director and 10% owner of Organogenesis Holdings Inc., transferred shares to his spouse, Josette Ades, as a gift for estate planning purposes on January 9, 2025.

A director of Organogenesis Holdings Inc. has transferred over 6 million shares to his spouse as part of an estate planning strategy, maintaining the same overall holdings within a group of controlling stockholders.

A significant transfer of Organogenesis Holdings Inc. Class A Common Stock occurred between members of a controlling group for estate planning purposes, with no change in the total group holdings.

A group of Organogenesis Holdings Inc. insiders, including Alan A. Ades, transferred shares to his spouse for estate planning purposes, with no change to the total number of securities held by the group.

Organogenesis Holdings CEO, Gary S. Gillheeney, sold a total of 61,200 shares of Class A Common Stock to cover tax obligations arising from a previous stock option exercise.

Organogenesis Holdings CEO, Gary S. Gillheeney, sold shares to cover withholding taxes related to a previous stock option exercise.

Organogenesis CEO Gary S. Gillheeney exercised stock options and sold shares to cover withholding taxes, while also selling additional shares on the open market.

A group of insiders at Organogenesis Holdings Inc., including the GN 2016 Family Trust, sold 500,000 shares of Class A common stock at a price of $4.057 per share.

Organogenesis Holdings Inc.'s insider group reports a significant stock transaction involving a 10% ownership group.

Multiple insiders of Organogenesis Holdings Inc., including directors and entities associated with them, have disposed of shares through a stock repurchase agreement, reducing their overall holdings.

Multiple insiders of Organogenesis Holdings Inc. sold shares back to the company through a stock repurchase agreement, reducing their holdings.

Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., reports disposition of shares to cover tax obligations.

Patrick Bilbo, Chief Operating Officer of Organogenesis Holdings Inc., reports disposition of shares to cover tax obligations.

Lori Freedman, Chief Admin. and Legal Officer of Organogenesis Holdings Inc., reports the disposition of 1,974 shares of Class A Common Stock to cover tax obligations.

Brian Grow, Chief Commercial Officer of Organogenesis Holdings Inc., reports the disposition of 1,977 shares of Class A Common Stock on April 1, 2024, to cover tax obligations.

Antonio S. Montecalvo, Vice President of Health Policy at Organogenesis Holdings Inc., disposed of 1,752 shares of Class A Common Stock on April 1, 2024, to cover tax obligations.

Gary S. Gillheeney, President and CEO of Organogenesis Holdings Inc., reports a transaction involving Class A Common Stock on April 1, 2024, resulting in a change in beneficial ownership.

Patrick Bilbo, Chief Operating Officer of Organogenesis Holdings Inc., exercised stock options to acquire 152,250 shares of Class A Common Stock at $1.18 per share on March 28, 2024.